Conference materials

2017

Zemplenyi A, Csanadi M, Pitter J, Kalo Z. Criteria identification and weight elicitation methods used in multiple criteria decision analysis (MCDA) of integrated care models. IME-META XI. Conference of the Hungarian Health Economics Association, oral presentation, Pecs 22-23 June, 2017 

Zemplenyi A, Csanadi M, Pitter J, Kalo Z, Voko Z, Csikos A. Economic evaluation of Palliative Care Consult Service in the framework of SELFIE Horizon 2020 project: study design. IME-META XI. Conference of the Hungarian Health Economics Association, poster presentation, Pecs 22-23 June, 2017 

Pitter J, Csanadi M, Nemeth B. Proportion of patient co-payment fee in the cost of medicines reimbursed at a fixed amount: patterns in Hungary by age, sex, geography and socioeconomic status. IME-META XI. Conference of the Hungarian Health Economics Association, poster presentation, Pecs 22-23 June, 2017 

Pitter J, Csanadi M, Zemplenyi A, Lukacs G, Moizs M, Kalo Z, Voko Z, Hodi Zs, Svebis M, Repa I. The SELFIE empirical study of OnkoNetwork: study protocol and current patient enrolment status. IME-META XI. Conference of the Hungarian Health Economics Association, poster presentation, Pecs 22-23 June, 2017 

Kalo Z. Health Economics 2017 - Quo Vadis? IME-META XI. Conference of the Hungarian Health Economics Association, oral presentation, Pecs 22-23 June, 2017 

Szilberhorn L. Cost-effectiveness and modeling approach of direct antiviral agents treating hepatitis-C. IME-META XI. Conference of the Hungarian Health Economics Association, oral presentation, Pecs 22-23 June, 2017 

Inotai A, Harsanyi A, Csanadi M, Kalo Z. Rethinking the biosimilar drug policy. IME-META XI. Conference of the Hungarian Health Economics Association, oral presentation, Pecs 22-23 June, 2017 

Nemeth B, Molnar A. Comparison of weighting methods used during the construction of multicriteria decision analysis models IME-META XI. Conference of the Hungarian Health Economics Association, poster presentation, Pecs 22-23 June, 2017 

Csanadi M, Kalo Z. Current and preferred status of HTA implementation in Central and Eastern European countries. IME-META XI. Conference of the Hungarian Health Economics Association, oral presentation, Pecs 22-23 June, 2017 

Agh T, Pitter JG, Nemeth B, Voko Z. Adherence to 5-Aminosalicylates and its Relation with Quality of Life and Health Care Resource Utilization in Patients With Inflammatory Bowel Disease: Evidence From US National Survey Data. PGI29, May 2017, ISPOR 22nd Annual International Meeting, Boston, MA, USA

Nemeth B, Molnar A, Akehurst R, Horvath M, Koczian K, Nemeth G, Gotze A, Voko Z. Estimating Difference in Quality Adjusted Life Year Gain for Patients with Predominant Negative Symptoms of Schizophrenia Treated with Cariprazine and Risperidone. PRM127, May 2017, ISPOR 22nd Annual International Meeting, Boston, MA, USA

Piniazhko O, Nemeth B. Practical Issues of Determining Weights for Criteria to Be Used in an MCDA Framework - Based on a Case-Study. PHP208, May 2017, ISPOR 22nd Annual International Meeting, Boston, MA, USA

Agh T, Voko Z, Heisel O, Chiva-Razavi S, Barbeau M, Szilberhorn L, Keown P. Prevalence of Psoriatic Arthritis: Is Psoriatic Arthritis Underdiagnosed in Psoriasis Patients Seen in Dermatology Clinics? 16th Caribbean Dermatology Symposium, Aruba; January 17–21, 2017, 41st Hawaii Dermatology Seminar, Maui, HI, USA; January 29–February 3, 2017

Szilberhorn L, Agh T, Fasseeh AN, Kalo Z. Cost-Effectiveness and Modeling Approaches of Direct-Acting Antiviral Agents in Chronic Hepatitis C Infection: A Systematic Literature Review VALUE IN HEALTH 20:(9) p. A411. 1 p. ISPOR 20th Annual European Congress, presentation, Glasgow, Scotland, 4-8 November, 2017

Molnar A. , Nagy B. , Kerpel-Fronius A. , Bajzik G. , Horvath I. , Moizs M. , Voko Z. Modelling Patient Pathways Of Low-Dose Computed Tomography Screening For Lung Cancer In Hungary. Value in Health 20:(9) p. A750. (2017) 

Szilberhorn L. , Korosi L. , Vajer P. , Nagy B. , Voko Z. Cost-effectiveness of controlling diabetes in primary care. The European Journal of Public Health 27:(Suppl. 3) p. 427. (2017)

 

2016

Kalo Z. How to Assess the Value of the Drug? An Overview on Producing Economic Evidence in the R&D Process.CLINICAL THERAPEUTICS 38:(10S) p. e14. EACPT Focus Meeting, Opatija, Croatia, 2016

Ansaripour A, Franken M, Uyl-de Groot C, Kalo Z, Redekop WK .PCN283 - Is External Reference Pricing A Threat to International Equal Affordability? VALUE IN HEALTH 19:(7) pp. A759-A760. ISPOR 19th Annual European Congress. Wien, Austria, 2016

Kaló Z ISPOR RARE DISEASES SPECIAL INTEREST GROUP REPORT: CHALLENGES IN ASSESSING AND APPRASING RARE DISEASE DIAGNOSTICS & TREATMENTS Pharmaca 52:(Supl. 1) p. 18. 6th Adriatic Congress of Pharmacoeconomics and Outcomes Research. Bled, Slovenia, 2016

Kalo Z, Vitezic D. Implementation of Pharmacoeconomics to Support Pharmaceutical R&D Decisions (Workshop) CLINICAL THERAPEUTICS 38:(10S) p. e19. EACPT Focus Meeting Opatija, Croatia, 2016

Nemeth B, Csanadi M, Kaló Z. Strenghts and weaknesses of HTA implementation in Hungary Pharmaca 52:(Supl. 1) p. 20. 6th Adriatic Congress of Pharmacoeconomics and Outcomes Research. Bled, Slovenia, 2016

Ragab S, Elsisi G, Hassan R, Aboushady R, Atef M, Kalo Z, Abaza S, Shaheen M. CHALLENGES THAT FACE THE APPLICABILITY OF MULTI-INDICATION PRICING FOR INNOVATIVE PRODUCTS IN EGYPT VALUE IN HEALTH 19:(3) p. A293. ISPOR 22st Annual International Meeting, Washington DC, USA, 2016

George M, Kalo Z, Abbas YM, Abaza S. Driving UHC In Emering Markets: an Egyptian Case VALUE IN HEALTH 19:(3) p. A290. ISPOR 22st Annual International Meeting, Washington DC, USA, 2016

Brixner D, Maniadakis N, Kaló Z, Hu S, Johnston A, Shen J, Wijaya KE. PHP4 - Application of Multi-Criteria Decision Analysis (MCDA) Scoring as an HTA Methodology for off-Patent Pharmaceuticals (OPP) in Emerging Markets VALUE IN HEALTH 19:(7) p. A815. 2016

Kalo Z, Vitezic D. Implementation of Pharmacoeconomics to Support Pharmaceutical R&D Decisions. Workshop at the EACPT Focus meeting (Opatija, 2016). Clin Ther. 2016 Oct 6;38(10S):e19. 

Kalo Z. How to Assess the Value of the Drug? An Overview on Producing Economic Evidence in the R&D Process. Oral presentation at the EACPT Focus meeting (Opatija, 2016). Clin Ther. 2016 Oct 6;38(10S):e14 

Nemeth B, Kulchaitanaroaj P, Lester-George A, Huic M, Pokhrel S, Kalo Z, Jozwiak-Hagymasy J, Nagy B. Identifying the Key Parameters of the European-study on Quantifying Utility of Investment in Protection From Tobacco (EQUIPT) Model, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Kaló Z, Voko Z, Clifton-Brown E, Vasilescu RS, David T, Gibson E, Begum N, Rao N. Impact of National Criteria and Healthcare System Characteristics on Access to Biologic Dmards in Rheumatoid Arthritis in Europe, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Nemeth B, Piniazhko O. MCDA Application in Central and Eastern Europe: Selection of the Most Important Criteria Based on Examples, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Csanadi M, Prins C, Grelinger E, Fricke F, Fuksa L, Tesar T, Manova M, Lorenzovici L, Kiss A, Kalo Z. Implication of External Price Referencing on Pharmaceutical List Prices in Europe, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Subtirelu M, Mic OC, Daneasa D, Csanadi M, Atikeler K, Dogan E, Preda AL. What is the Level of Transparency in Health Technology Assessment Process in Hungary, Romania and Turkey? ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Inotai A, Csanadi M, Petrova G, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Araja D, Lorenzovici L, Egyed K, Kalo Z. Mapping of the Biosimilar Drug Policy in 10 Central Eastern European Countries, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Eder B, Nagy B. Budget impact analysis guideline: international and Hungarian perspective, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Inotai A, Prins C, Csanadi M, Csetneki K, Szegner P, Vitezic D, Kalo Z. A Real Concern or Just a Hype? – Evidence on Negative Clinical Consequences of Switching From Originator to Biosimilar Based on a Systematic Literature Review, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Agh T. Comparative Analysis of Medication Possession Ratio Measures for Adherence to Single-Medication, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Bochenek T, Godman BB, Bucsics A, De Weerdt E, Fürst J, Gailite E, Hotvedt TA, Huys I, Inotai A, Joppi R, Malaj A, Margus K, Marković-Peković V, Simoens S, Slaby J, Sović Brkičić L, Gürpınar EU, Vella Bonanno P, Warminska EJ, Pilc A. Systemic Solutions, Legislative and Organizational Frameworks Aimed to Prevent or Mitigate Drug Shortages in European Countries, ISPOR 19th Annual European Congress, poster, Vienna, Austria, 29 October - 2 November, 2016

Agh T. The Value of Multi-Stakeholder Partnership in Advancing Patient Access in Central and Eastern Europe, ISPOR 19th Annual European Congress, oral presentation, Vienna, Austria, 29 October - 2 November, 2016 

Kalo Z, Krasnova L, Perikhanyan A, Petrova G, Pyadushkina E. Burden of Hepatitis C in Central and Eastern European Countries, ISPOR 19th Annual European Congress, oral presentation, Vienna, Austria, 29 October - 2 November, 2016 

Kalo Z, Knies S, Mandrik O, Severens H. How to Transfer Economic Evidence to Low and Middle-Income Countries? Working Under Capacity Restrictions, ISPOR 19th Annual European Congress, oral presentation, Vienna, Austria, 29 October - 2 November, 2016 

Agh T. Measuring Multiple Medication Adherence – Which Measure When?, ISPOR 19th Annual European Congress, oral presentation, Vienna, Austria, 29 October - 2 November, 2016 

Elek P, Harsányi A, Zelei T, Csetneki K, Kalo Z.Policy Objective of Generic Medicines from the Investment Perspective: The Case of Clopidogrel, ISPOR 19th Annual European Congress, oral presentation, Vienna, Austria, 29 October - 2 November, 2016 

Tesar T, Hren R, Inotai A, Hlade Zore D. Extending the Use of Biosimilar Drugs: Are We Willing to Accept the Uncertainty Related to Switching in Order to Improve Patient Access To Modern Medicines? ISPOR 19th Annual European Congress, oral presentation, Vienna, Austria, 29 October - 2 November, 2016 

Nemeth B. ISPOR Hungary Chapter Meeting moderator, ISPOR 19th Annual European Congress, oral presentation, Vienna, Austria, 29 October - 2 November, 2016 Link

Hren R, Kalo Z, Kolasa K. Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements, ISPOR 19th Annual European Congress, short course, Vienna, Austria, 29 October - 2 November, 2016 

Agh T, Voko Z, Heisel O, Chiva-Razavi S, Barbeau M, Szilberhorn L, Keown P. Prevalence of psoriatic arthritis: is psoriatic arthritis underdiagnosed in psoriasis patients seen in dermatology clinics? [poster] 25th EADV Congress, Vienna, Austria, 28 September - 2 October, 2016

Nemeth B. Return on Investment - the Economics in Public Health. 4th International Congress on Health Economics and Outcomes Research. Belgrade, Serbia. 23-24 September 2016

Zsolyom A, Szilberhorn L, Nemeth B, Nagy B, Voko Z. Impact of adjusting diabetes treatment pathways according to disease severity - The case of HbA1c and macular oedema. Economics Modelling and Diabetes: The Mount Hood 2016 Challenge, oral presentation, St Gallen, 16-18th September 2016

Kalo Z. What can CEE and wider countries learn from EQUIPT: transferability of economic models at its best. 11th European Conference On Health Economics - EUHEA Conference, oral presentation, Hamburg, Germany, 13-16 July 2016 

Zemplenyi A, Pitter J, Csanadi M, Csetneki K, Kaló Z. Evaluating Integrated Care Models with Multiple Criteria Decision Analysis Methods. IME-META X. Conference of the Hungarian Health Economics Association, oral presentation, Budapest 15-16 June, 2016 

Nemeth B. Presentation of the EQUIPT Tobacco ROI Tool including policy proposals for selected Central and Eastern European countries & Presentation of post-workshop survey results. EQUIPT International Workshop, oral presentation, Zagreb, Croatia, 3 June, 2016

Eder B, Nagy B. Review of budget impact analysis methods, Hungarian and international review IME-META X. Conference of the Hungarian Health Economics Association, oral presentation, Budapest, 15-16 June, 2016 

Joo T, Voko Z. The effects of tobacco control measures. Have smoking ​decreased in Hungary? X. Hungarian Health Economic Training and Conference, oral presentation, Budapest, 15th and 16th June, 2016 

Almasi T, Szilberhorn L, Nagy B. Multi-step screening strategies to recognize type 2 diabetes mellitus. IME-META X. Conference of the Hungarian Health Economics Association, oral presentation, Budapest,15-16 June, 2016 

Jakab I, Nagy B, Szeker V, Kocsis T, Nagyjanosi L, Kalo Z. Evidence based reimbursement decisions on medical devices in Hungary. IME-META X. Conference of the Hungarian Health Economics Association, oral presentation, Budapest 15-16 June, 2016 

Pitter J, Csanadi M, Zemplenyi A, Csetneki K, Moizs M, Kalo Z, Repa I. Identification of integrated care models for patients with multimorbidity in Hungary. IME-META X. Conference of the Hungarian Health Economics Association, oral presentation, Budapest, 15-16 June, 2016 

Agh T, Voko Z, Heisel O, Chiva-Razavi S, Barbeau M, Szilberhorn L, Paul Keown. Systematic literature review of the prevalence of psoriatic arthritis. Annual Congress, of Rheumatology, 2016, London, United Kingdom

Turi G, Zsolyom A, Voko Z. The cost-effectiveness of oral cancer screening in Hungary. X. Hungarian Health Economic Training and Conference, Budapest, 15th and 16th June, 2016 

Voko Z, Zsolyom A, Jermendy Gy. Diabetes ​attributable mortality in Hungary. X. Hungarian Health Economic Training and Conference, oral presentation, Budapest, 15th and 16th June, 2016 

Nemeth B, Kulchaitanaroaj P, Lester-George A, Huic M, Pokhrel S, Kalo Z. Identifying the Key Parameters of the European-Study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT) model. X. Hungarian Health Economic Training and Conference, Budapest, 15th and 16th June, 2016 

Nemeth B. Filling the gaps in HTA system - ISPOR views, The First CEE ISPOR Network Cross-boarder joint meeting, oral presentation, Bratislava, Slovakia, 6 May, 2016 Link

Freijer K, Pitter J, Volger S. The DO’S and DON’TS of Performing A Scoping Review: Examples from the literature, ISPOR 21th Annual International Meeting, oral presentation, Washington DC, USA, 21-25 May, 2016 

Bunz TJ, Malmenas M, Agh T, Pednekar P. A framework for measuring multiple medication adherence. ISPOR 21th Annual International Meeting, oral presentation, Washington DC, USA, 21-25 May, 2016 

Kvizhinadze N, Piniazhko O, Zah V, Krasnova L, Agh T. Development and application of multi-criteria decision analysis in Central & Eastern Europe (CEE) in cooperation with western countries. ISPOR 21th Annual International Meeting, oral presentation, Washington DC, USA, 21-25 May, 2016 

Nemeth B. Strenghts and weaknesses of HTA implementation in Hungary. 7th ISPOR Adriatic Congress, oral presentation, Bled, Slovenia, 21 April 2016 

Csanadi M. Implementing a health technology assessment system in lower income EU member states. National Congress of Romanian Student Pharmacists, oral presentation, Craiova, Romania, 2 April, 2016

Csanadi M. Education in focus - Human capacity building in health policy and health economics. National Congress of Romanian Student Pharmacists, oral presentation, Craiova, Romania, 2 April, 2016

 

2015

Garrison LP, Kalo Z: Making Sense of Risk-Sharing and Managed Entry Agreements, AMCP 2015 Nexus, 26-29 October, Orlando FL 

Kristensen FB, Kolasa K, Huic M, Kaló Z. BUILDING LIGHT HTA APPROACH IN CENTRAL AND EASTERN EUROPEAN COUNTRIES BASED ON HTA RECOMMENDATIONS IN WESTERN EUROPEAN COUNTRIES: MORE HARM THAN GOOD? ISPOR 18th Annual European Congress, Milan, Italy, November, 2015. Link

Lanitis T, Kalo Z, Muszbek N. UNCERTAINTY OF UNCERTAINTY ESTIMATES IN ECONOMIC MODELLING OF ONCOLOGY. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015. 

Zemplenyi A, Kalo Z, Boncz I, Endrei D, Mangel L. A Microcosting Study of Radiation Therapy in Localized Prostate Cancer Patients in a Hungarian Tertiary Oncology Center. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015, Value Health. 2015 Nov;18(7):A354. 

Ragab S, Diaa M, Hassan R, Abou Shady R, El-Sisi G, Kalo Z, Abaza S, Shaheen M, Abbas Y. Pricing Policy for Pharmaceuticals in Egypt: Challenges and Opportunities. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015, Value Health. 2015 Nov;18(7):A523. 

Kalo Z, Csanadi M, Vitezic D, Huic M, Husereau D, Kristensen FB. Comparison of current and preferred status of HTA implementation in Central and Eastern European countries. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015, Value Health. 2015 Nov;18(7):A538. 

Csanadi M, Fasseeh AN, Kalo Z. Methodology of International Comparison of Pharmaceutical Prices. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015Value Health. 2015 Nov;18(7):A539 

Hegazy A, George M, Kalo Z, Abaza S, Abbas YM, Atef M. Challenges Along the Road to Universal Health Coverage in Egypt, an HIO Perspective. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015, Value Health. 2015 Nov;18(7):A567-8. 

Pitter JG, Vokó Z, Halmos Á, Józwiak Á. Cost-utility analysis of potential campylobacter control measures in the food chain of indoor broiler chicken in the EU. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015 

Nemeth B. How Pharmacoeconomics Should Be Applied to Support Decisions in Lower Income European Countries? ISPOR 18th Annual European Congress, oral presentation, Milan, Italy, November, 2015 

Nemeth B, Csordas A, Papp E. The cumulative analysis of checklist questionnaires filled out by the Hungarian HTA Office. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015

Nemeth B, Eder B. Assessing the cost-effectiveness of therapies in the third quadrant on the cost-effectiveness plane. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015

Kocsis T, Papp E, Nemeth B, Juhasz J. The cost of treatment of the new antiviral therapies against the Hepatitis C virus. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015

Agh T, Bodnar R, Olah M, Meszaros A. Adherence to inhaled antibiotics for the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis: a systematic literature review. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015 

Agh T, Inotai A, Szilberhorn L, Culig J, Petrova G, Visnansky M, Kalo Z. A novel method for calculating medication adherence to poly-pharmacotherapy by linking general practice prescribing data and pharmacy dispensing records. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015 

Agh T, Pawaskar M, Nagy B, Szilberhorn L, Voko Z. Budget impact analysis of introducing lisdexamfetamine dimesylate for the treatment of binge eating disorder in the United States. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015. 

Voko Z, Pawaskar M, Agh T, Merész G, Wadden T, Herman BK. Characterization of health-related quality of life and healthcare utilization and cost in adults with binge eating disorder in a US population. 65th Annual Meeting of the Canadian Psychiatric Association, Vancouver, BC, Canada, 2015. 

Agh T, Pawaskar M, Voko Z, Nagy B, Lachaine J. The cost-effectiveness of lisdexamfetamine dimesylate for the treatment of binge eating disorder. ISPOR 20th Annual International Meeting, Philadelphia, PA, USA, 2015. 

Inotai, Csanadi M, Hanko B, Kalo Z. Principles Of Policy Framework In The Pharmaceutical Wholesale And Retail System In Lower Income European Countries. IX. Hungarian Health Economic Training and Conference, oral presentation, Budapest, 24th and 25th June, 2015

Meresz G, Csetneki K, Inotai A, Kalo Z. International Comparison Of Pharmaceutical Expenditures In Central-Eastern European Countries: Methodological Questions. IX. Hungarian Health Economic Training and Conference, oral presentation, Budapest, 24th and 25th June, 2015

Tamas Agh, Katalin Gaspar, Balazs Nagy, Zoltan Kalo. Value of a newborn child. IX. Hungarian Health Economic Training and Conference, oral presentation, Budapest, 24th and 25th June, 2015

Voko Z. Question marks about the efficacy of breast cancer screening - a case-study about the difficulties of evidence-based health policy. IX. Hungarian Health Economic Training and Conference, oral presentation, Budapest, 24th and 25th June, 2015

Pitter GJ, Voko Z, Halmos A, Jozwiak A. Need for Reliable Disease Burden Estimates to Support Food Safety Decision Making: the example of Human Campylobacteriosis in the European Union. IAFP's European Symposium on Food Safety - Cardiff, Wales, oral presentation (20-22 April, 2015)

Pitter GJ, Voko Z, Halmos A, Jozwiak A. Cost-utility analysis of potential Campylobacter control measures in the food chain of indoor broiler chicken in the EU. IX. Hungarian Health Economic Training and Conference, Budapest, 24th and 25th June, 2015

Zsolyom A, Nagy B, Nagyjanosi L, Dessewffy Z, Steiner T, Kalo Z, Voko Z. Cost-effectiveness of introducing a risk stratified screening questionnaire (FINDRISC) for type 2 diabetes. IX. Hungarian Health Economic Training and Conference, oral presentation, Budapest, 24th and 25th June, 2015

Inotai A, Csanadi M, Hanko B, Kalo Z. (2015) Principles of policy framework in the pharmaceutical wholesale and retail system in lower income European countries. Value in Health. Vol 18, (3), Page A74. ISPOR XX. Annual congress (Philadelphia) 16-20 May 2015. 

Agh T, Pawaskar M, Voko Z, Nagy B, Lachaine J. The cost-effectiveness of lisdexamfetamine dimesylate for the treatment of binge eating disorder. ISPOR 20th Annual International Congress Philadelpia, USA, May, 2015 

 

2014

Gregory V, Barbeau M, Machnicki G, Voko Z, Heisel O, Keown, P. Real world research in Latin America: oportunities, sources and barriers. ISPOR 19th Annual International Congress Montreal, Canada, June, 2014.

Agh T, Pawaskar M, Kovacs G, Kalo Z, Supina D, Voko Z. The Humanistic and economic burden of bulimia nervosa and binge eating disorder: a systematic review. ISPOR 19th Annual International Congress Montreal, Canada, June, 2014.

Inotai A, Kalo Z, Vitezic D, Petrova G. PHP137 Transferability Of International Evidence On The Benefits Of Innovative Medicines Into Central Eastern European Countries. ISPOR 19th Annual International Congress Montreal, Canada, June, 2014

Kalo Z, Ibrahim Alabbadi, Ola Ghaleb Al Ahdab, Daoud Al-Badriyeh, Maryam Alowayesh, Abdulaziz H Al-Saggabi , Mahmoud Elmahdawy, Vito Luigi Tanzi, Faleh Mohamed Hussain Ali, Hamad S Alsultan, Gihan H Elsisi, Kasem S Akhras, Voko Z, Panos Kanavos. PHP25 IMPLICATIONS OF EXTERNAL PRICE REFERENCING OF PHARMACEUTICALS IN MIDDLE EAST COUNTRIES. ISPOR 17th Annual European Congress Amsterdam, The Netherland, 2014 

Inotai A, Abonyi-Toth Z, Rokszin G, Voko Z. PRM57 Occurrence, survival and annual cost of colorectal-, breast-, prostate- and lung cancer in Hungary. ISPOR 17th Annual European Congress Amsterdam, The Netherlands, November, 2014

Kalo Z, Vamossy I, Harsanyi A. Investment aspects of generic drug policies in countries with severe resource constraints. ISPOR 17th Annual European Congress Amsterdam, The Netherland, 2014 

Zsolyom A, Nagy B, Nagyjanosi L, Dessewffy Z, Steiner T, Kalo Z, Voko Z. PDB148 Cost-effectiveness of the introduction of an organized adherence program for type 2 diabetes in Hungary. ISPOR 17th Annual European Congress Amsterdam, The Netherlands, November, 2014 

Lorenzovici L, Szekely A, Agh T, Vamossy I, Kelemen L, Finta H, Kalo Z. PIH33 Economic evaluation of ulipristal acteate for the treatment of patients with moderate and severe symptoms of uterine fibroids in Romania. ISPOR 17th Annual European Congress Amsterdam, The Netherland, 2014 

Meresz G., Foldesi Cs., Nagyistok Sz., Vincziczki A. Z.: The publication activity of the Hungarian Health Economics Association. IME-META VIII. National Health Economic Training and Conference, poster and presentation, Budapest, 18th and 19th of June, 2014.

Meresz G.: Analysing scientometric data to relevate publication activity and coauthor networks. Hungarian Natural Language Processing Meetup, 26th September 2014. 

Meresz G., Gyurcsan G. Cs., Salfer B.: Easy Come, Hardly Go: Epidemiological Methods to Evaluate the Effect of Ispor Board of Directors Membership on Publication Activity. Value in Health , Volume 17, Issue 7 , A555. 

Meresz G.: Coauthor networks: beyond citations. Budapest Business Intelligence Forum, 26th November 2014. 

Gaspar K, Kalo Z, Agh T, Vamossy I, Lehmann M, Nagy B:PRM23 The long-term economic value of a new-born child comparison of the human capital and the lifetime investment approaches. ISPOR 19th Annual International Meeting, Montreal, Canada, May, 2014 

Zsolyom A, Nagy B, Dessewffy Z, Steiner T, Kalo Z, Voko Z: PDB123 Cost-effectiveness of the introduction of a risk stratified population screening for type 2 diabetes in Hungary. ISPOR 19th Annual International Meeting, Montreal, Canada, May, 2014 

 

2013

Agh T, Meszaros A. Association of medication adherence and quality of life in patients with COPD. ESPACOMP 17th Annual Meeting Budapest, Hungary, November, 2013 

Zsolyom A, Meresz G, Nagyjanosi L, Nagyistok Sz, Nagy B, Kalo Z, Voko Z: PRM87 External validation of the Syreon Diabetes Model. ISPOR 16th Annual European Congress Dublin, Ireland, November, 2013 

Agh T, Inotai A, Bartfai Z, Meszaros A: PRS47 Relationship between medication adherence and quality of life in COPD – systematic review. ISPOR 16th Annual European Congress Dublin, Ireland, November, 2013 

Abonyi-Toth Zs, Kalo Z, Agh T, Inotai A, Katona L, Rokszin Gy, Jozwiak-Hagymasy J. PCV148 Assessment of generic drug policy implementation by measuring persistence with antihypertensive drug therapies after patent expiry. ISPOR 16th Annual European Congress Dublin, Ireland, November, 2013 

Kalo Z, Abonyi-Toth Zs, Rokszin Gy, Katona L, Agh T, Inotai A. PCV147 Impact of multiple switching on health care costs and outcomes in generic drug policies. ISPOR 16th Annual European Congress Dublin, Ireland, November, 2013 

Vamossy I, Agh T, Blasszauer C, Bago M, Meszaros A, Kalo Z. PIH53 Societal burden of hysterectomy in reproductive-aged women with uterine fibroids. ISPOR 16th Annual European Congress Dublin, Ireland, November, 2013 

Nagyistok Sz, Szilberhorn L, Nagy B,Kalo Z: Cost-benefit analysis of KMOP tender - Opportunity or curse? VII. Hungarian Health Economic Training and Conference, poster, Budapest, 19th and 20th of June, 2013 

Nagyistok Sz, Borsi A, Sinkovits B: Multivariate data analysis of META sessions. VII. Hungarian Health Economic Training and Conference, poster, Budapest, 19th and 20th of June, 2013 

Zsolyom A, Dr. Csicsari K: Nurse scheduling of the Pulmonary Institute in Eger. VII. Hungarian Health Economic Training and Conference, poster, Budapest, 19th and 20th of June, 2013 

Boehler C, Meresz G, Kalo Z: PHP65 Pharmaceutical spending levels across Europe – Consequences of current international pricing policies on lower income countries. ISPOR 18th Annual International Meeting. Poster, New Orleans, May 18-22th of 2013. 

Meresz G, Kobori L, Mocsari D, Kosoczki E, Hirka G, Monostory K, Kalo Z: Personalized medicine in kidney transplantation: health economic analysis of the CYPtestTM diagnostic method. VII. Hungarian Health Economic Training and Conference, presentation, Budapest, 19th and 20th of June, 2013

Boehler C, Kalo Z: A new spectre is haunting Europe! External price referencing and its impact lower income European economies, VII. Hungarian Health Economic Training and Conference, presentation, Budapest, 19th and 20th of June, 2013

Soroncz-Szabo T, Helter T, Nagy B, Kalo Z, Bischof M, Hodgkins P, Erder MH, Setyawan J: Attention deficit/hyperactivity disorder: Are all the costs, benefits and outcomes being captured in economic evaluations? Atten Defic Hyperact Disord 2013 June;5(2):246 

Boehler C: A new spectre is haunting Europe! International price referencing and its impact on lower income European economies, III. Croatian and III. Adriatic Congress on Pharmacoeconomics and Outcomes Research, "The Role of Farmacoeconomics in Developing Countries",Brijuni, Croatia, April 25-27, 2013, 

Helter T: Moving beyond QALYs - measuring and valuing outcomes of alcohol misuse interventions, III. Croatian and III. Adriatic Congress on Pharmacoeconomics and Outcomes Research, "The Role of Farmacoeconomics in Developing Countries",Brijuni, Croatia, April 25-27, 2013

Kalo Z: Contribution of clinical trials to the economy in Central-Eastern Europe - the case of Hungary, III. Adriatic Congress on Pharmacoeconomics and Outcomes Research, "The Role of Farmacoeconomics in Developing Countries",Brijuni, Croatia, April 25-27, 2013

 

2012

Kalo Z, Vitezić D. Applied pharmacoeconomics: How pharmacoeconomics can be applied to support decisions by different stakeholders in health care? First Bosnian-Hezegovinian and Second Adriatic Congress on Pharmacoeconomics and Outcomes Research, Sarajevo, Bosnia and Herzegovina, April 24-26, 2012, Folia medica Facultatis Medicinae Universitatis Saraeviensis 2012; 47 (Supp.1): 10-11.

Agh T, Inotai A, Meszaros A: PIH33 Utility and human capital loss in asthma, chronic obstructive pulmonary disease and rheumatoid arthritis - The impact of prevalence, disease specific mortality and utility decrement on overall health burden. ISPOR 15th Annual European Congress Berlin, Germany, November, 2012 

Jozwiak-Hagymasy J, Meresz G, Dr. Marton I, Nagyjanosi L, Nagyistok Sz, Dessewffy Z, Nagy B, Voko Z, Kalo Z: Quantifying costs and utilities for the health economic model to compare the prevention, treatment and management strategies of type 2 diabetes. VI. Hungarian Health Economic Training and Conference 2012. June 21th. 

Agh T, Inotai A, Meszaros A: Health burden of asthma, COPD and rheumatoid arthritis in Hungary. VI. Hungarian Health Economic Training and Conference 2012. June 21th.

Kalo Z, Inotai A, Meresz G: PHP44 International Comparison of Pharmaceutical Expenditure in Middle Income Countries: Methodological Questions ISPOR 17th Annual International Meeting Washington, D.C., USA, June, 2012 

Meresz G, Nagyjanosi L, Nagy B, Dessewffy Z, Voko Z, Kalo Z: PRM85 Internal validation of the Syreon diabetes model ISPOR 15th Annual European Congress Berlin, Germany, November, 2012 

Nagy B, Jozwiak-Hagymasy J, Timar Gy, Kovacs G, Meresz G, Vamossy I, Agh T, Voko Z, Kalo Z: PIH24 Economic evaluation of ulipristal acetate tablets for the treatment of patients with moderate and severe symptoms of uterine fibroids ISPOR 15th Annual European Congress Berlin, Germany, November, 2012 

Ward S, Nagy B, Gray L: Cost-effectiveness analysis of three year versus one year imatinib for the treatment of patients at high risk of disease recurrence following surgical resection of KIT (CD117) positive gastrointestinal stromal tumours (GIST). European Society of Medical Oncology 2012, Wien, Austria, September 29th 

Kalo Z: Capability Building in Health Economics. Oral presentation at the Pricing & Reimbursement Future Trends Workshop for Egypt, Sharm El-Sheik, Egypt, May 2012

Kalo Z: Patient access to pharmaceuticals in Eastern Europe: Differential pricing for Low and Middle Income countries. Oral presentation at the Pricing & Reimbursement Future Trends Workshop for Egypt, Sharm El-Sheik, Egypt, May 2012

Kalo Z: Managed Entry Agreements - Patient Access Schemes. Oral Presentation at the 1st Middle East Africa Pricing & Reimbursement Future Trends Workshop, Muscat, Oman, 2012

Kalo Z: HTA Capability Building. Oral Presentation at the 1st Middle East Africa Pricing & Reimbursement Future Trends Workshop, Muscat, Oman, 2012

Kalo Z: Pricing and reimbursement of pharmaceuticals in Central-Eastern European countries. Oral presentation at the Symposium on the “Pricing and Reimbursement of Medicines – European Practices” under the patronage of the Parliamentary Committee to the 41st National Assemble, Sofia, Bulgaria, 2012

Kalo Z: Heading of Pharmacoeconomics and Possibilities of the Cross-Border Cooperation - View of ISPOR. Oral presentation at the Conference on the Optimalisation of Methods of Pharmacoeconomics and Health Technology Assessment: Importance for National Health Policy and Cross-Border Cooperation, Bratislava, WHO Office Slovakia, 2012.

Kalo Z: Optimalisation of Methods of Pharmacoeconomics And Health Technology Assessment Methods in Hungary. Oral presentation at the Conference on the Optimalisation of Methods of Pharmacoeconomics and Health Technology Assessment: Importance for National Health Policy and Cross-Border Cooperation, Bratislava, WHO Office Slovakia, 2012.

Kalo Z: Development of Pharmacoeconomics and Potential of its Application as a Modern Tool of the Medicine Policy in the World and in Europe. Oral presentation at the Conference on the Optimalisation of Methods of Pharmacoeconomics and Health Technology Assessment: Importance for National Health Policy and Cross-Border Cooperation, Bratislava, WHO Office Slovakia, 2012.

Zemplenyi A, Endrei, D, Boncz, I, Kalo Z: PHP96 Evidence Based Structural Reform in the Provision of Hospital Care: The Case Study of Merging Two Institutions in Hungary. ISPOR 15th Annual European Congress Berlin, Germany, November, 2012 

Penzes, M, Kalo Z, Pozsgay C, Kalotai Z: PHP31 The Value of Investigational Medical Products. ISPOR 15th Annual European Congress Berlin, Germany, November, 2012 

Meszaros A, Agh T, Bartfai Z, Orosz M: Quality of life decrement and health burden in asthma and COPD. 57th Congress of Hungarian Respiratory Society, Budapest, Hungary, 14-16.06.2012.

Meszaros A, Agh T: Adherence and quality of life in patients with COPD. 18th Congress of Hospital Pharmacists, Szeged, Hungary, 17-19.05.2012.

 

2011

Agh T, Inotai A, Meszaros A: PRS62 Comparison of generic and disease specific quality of life measures in chronic obstructive pulmonary disease. ISPOR conference, Madrid, Spain, 2011 

Inotai A, Meresz G, Jozwiak-Hagymasi J, Kalo Z: Burden of disease model of disease-related malnutrition in Europe. V. Hungarian Health Economic Training and Conference, presentation, Budapest, 29th and 30th of June, 2011 

Kalo Z: Can we alleviate current market failures from international price referencing of pharmaceuticals in middle income countries? View of an academic expert from a middle income country, Issue Panel oral presentation at ISPOR 14th Annual European Congress, Madrid, Spain, 2011 

Kalo Z, Boncz I: Implications of economic crisis on health care decision-making in Hungary, Regional Forum oral presentation ISPOR 14th Annual European Congress, Madrid, Spain, 2011 

Kalo Z, Landa K, Dolezal T, Voko Z: PCN116 Transferability of Nice recommendations for pharmaceutical therapies in oncology to Central-Eastern European Countries ISPOR 16th Annual International Meeting Baltimore, MD, USA, May, 2011 

Kalo Z, Voko Z: Health technology assessment: a European collaboration. ExpertRev Pharmacoecon Outcomes Res. 2011 Feb;11(1):41-3. 

Nagy B, Nagyjanosi L, Nagyistok Sz, Jozwiak-Hagymasy J, Dessewffy Z, Meresz G, Kalo Z, Voko Z: PDB82 Development of a Health Economic Model to Compare the Prevention, Treatment and Management Strategies of Type 2 Diabetes. ISPOR 14th Annual European Congress Madrid, Spain, November, 2011 

Nagy B, Nagyjanosi L, Nagyistok Sz, Jozwiak-Hagymasy J, Dessewffy Z, Kalo Z, Voko Z: Development of a health economic model to compare the prevention, treatment and management strategies of type 2 diabetes. V. Hungarian Health Economic Training and Conference 2011. June 30th 

Nagyjanosi L, Martos E, Bodonyi D, Voko Z: PCV67 A health-economic analysis of salt intake reduction in Hungary ISPOR 14th Annual European Congress Madrid, Spain, November, 2011 

Nemeth J, Nagyjanosi L, Nagyistok S, Tolnayne Csattos M, Szabone Berta I, Kincse E, Szulyak E, Boer I, Hundzsa G, Kalo Z, Berta A: PSS17 Societal Burden of Blindness in Hungary ISPOR 14th Annual European Congress Madrid, Spain, November, 2011 

Meresz G, Inotai A, Kalo Z: Assessment of the pharmaceutical expenditure in Hungary, V. Hungarian Health Economic Training and Conference, presentation, Budapest, 29th and 30th of June, 2011

Skoupa J, Orlewska E, Kalo Z, Hajek P: PCN121 Challenges in Conducting Pharmacoeconomic Analyses in Central and Eastern Europe – Case Study on Breast Cancer ISPOR 14th Annual European Congress Madrid, Spain, November, 2011

Kalo Z: Feasibility of HTA implementation in Central-Eastern European countries. Oral presentation at the The Value of Innovation – HTA in Dialogue with the experts, AmCham / LAWG meeting, Bucharest, Romania, 2011

Kalo Z: Current Structure and Future of Pricing and Reimbursement in European Middle Income countries. Oral presentation at the SECOND INTERNATIONAL SEMINAR ON HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT: How does HTA support Value for Money? Bandung, Indonesia, 2011

Kalo Z: Principles for a good HTA. Oral presentation at the SECOND INTERNATIONAL SEMINAR ON HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT: How does HTA support Value for Money? Bandung, Indonesia, 2011

Inotai A, Meresz G, Kalo Z: PHP73 Government Reduces Public Pharmaceutical Expenditure in Hungary: Rational Decisions in Challenging Economic times?. ISPOR 14th Annual European Congress Madrid, Spain, November, 2011 

Szepesi G, Kalo Z, Antal J, Szepezdi Zs, Nagyjanosi L: Economic impact of clinical trials on the GDP, Oral presentation at the 10th European Association for Clinical Pharmacology and Therapeutics (EACPT) Congress, Budapest, Hungary 2011

 

2010

Botlik O, Kalotai Z, Dessewffy Z, Kalo Z: PHP34 Patient access to innovative medicines in Hungary ISPOR 13th Annual European Congress Prague, Czech Republic, November, 2010 

Kalo Z, Nagyjanosi L.: PUK14 Healthcare cost of renal replacement therapy in Hungary. ISPOR 13th Annual European Congress, Praga, Czech Republic, 2010 Link

Kalo Z, Nagyjanosi L, Kovacs G, Nagyistok Sz: PHP122 Competitiveness of Hungary in international clinical trials ISPOR 13th Annual European Congress Prague, Czech Republic, November, 2010 

Meszaros A, Agh T: PRS36 Adherence to medication and health-related quality of life in patients with COPD: SGRQ - an alternative method to identify non-adherence. ISPOR 13th Annual European Congress Prague, Czech Republic, November, 2010

Kalo Z, Nemeth A, Jozwiak-Hagymasy J: PMH48 Impact of once-daily dosing on drug discontinuation of patients with schizophrenia ISPOR 13th Annual European Congress Prague, Czech Republic, November, 2010

Nagy B, Nagy J, Alegre P: PMH32 Economic evaluation of agomelatine in major depresive disorders in Hungary. ISPOR 13th Annual European Congress Prague, Czech Republic, November, 2010 

Nagy B, Rakonczai P: Risk sharing methods applied with capitation payment in Hungary: a trade-off between selection and efficiency. IV.Hungarian Health Economic Training and Conference 2010. June 30th 

Orosz M, Galffy G, Agh T, Kovacs D, Meszaros A: The everyday life of patients with asthma or COPD. 56th Congress of Hungarian Respiratory Society, Sopron, Hungary, 2-5.05.2010.

Agh T, Bartfai Z, Meszaros A: Relation of adherence to quality of life in COPD patients. 56th Congress of Hungarian Respiratory Society, Sopron, Hungary, 2-5.05.2010.

Nagyjanosi L, Kalo Z: PHP13 Implementation of the transparency directive in Hungary, ISPOR 13th Annual European Congress. Praga, Czech Republic., 2010 

Voko Z, Nagyjanosi L, Kalo Z, Margitai B, Koos T, Kovi R: Economic evaluation of cervical cancer screening strategies. IV. Hungarian Health Economic Training and Conference, 2010, Budapest, Hungary

Voko Z, Nagyjanosi L, Kalo Z, Margitai B, Koos T, Kovi R: Economic evaluation of cervical cancer screening strategies. 8th European Conference on Health Economics. 2010, Helsinki, Finnland

Voko Z, Nagyjanosi L, Kalo Z: PCN103 Cost-effectiveness analysis of adding HPV vaccination to cervical cancer screening program in Hungary. ISPOR 13th Annual European Congress, Praga, Czech Republic., 2010 

Voko Z, Nagyjanosi L, Kalo Z: PDB24 Direct health care costs of diabetes mellitus in Hungary, ISPOR 13th Annual European Congress, Prague, Czech Republic, 2010 

Herczeg B, Hoschek P M, Molnar M Z, Kalo, Z: (2010). Clinical and Socio-Demographic Determinants of Utility Among Patients With Renal Transplantation: 2796. Transplantation, 90, 107. (XXIII International Congress of The Transplantation Society, Vancouver BC, 2010) 

Kalo Z, Marton J. Mihaly S, Gerendy P, Kiss Z: (2010). Cost-Benefit Analysis of Extended Donor Coordinator System To Increase Organ Donation Rates in Hungary: 2741. Transplantation, 90, 250. (XXIII International Congress of The Transplantation Society, Vancouver BC, 2010) 

Kalo Z: (2010). Comparison the Economic Value of Different Types of Organs in Renal Transplantation: 1866. Transplantation, 90, 251. (XXIII International Congress of The Transplantation Society, Vancouver BC, 2010) 

Kalo Z, Kiss Z, Gerendy P, Nagyjanosi L, Voko Z: (2010). Cost of Renal Replacement Therapy in Hungary: 2749. Transplantation, 90, 735. (XXIII International Congress of The Transplantation Society, Vancouver BC, 2010) 

Kalo Z: Role of HTA and transparent decision-making criteria to improve the access of patients to medical devices, Oral presentation at the EUCOMED MedTech Forum, Brussels, Belgium, 2011

Kalo Z: Cost effectiveness and reimbursement of lung cancer treatment expenses in the region. Oral presentation at the 12th Central-European Lung Cancer Conference, Budapest, Hungary, 2010

Kalo Z: Access of patients to innovative oncology therapies in European countries, Oral presentation at the 8th Congress of The Balkan Union of Oncology, Sibiu, Romania, 2010

Meszaros A, Agh T: PRS36 Adherence to medication and health-related quality of life in patients with COPD: SGRQ – an alternative method to identify non-adherence. ISPOR 13th Annual European Congress, Prague, Czech Republic, 2010 

Agh T, Meszaros A: Medication adherence in patients treated for COPD. European Society for Patient Adherence, Compliance and Persistence (ESPACOMP). Lodz, Poland, 17-18.09.2010.

 

2009

Karamustafalioglu O, Ozdemir O, Kalo Z: PMH43 The Cost-Effectiveness of Quetiapine XR in the Prevention of Relapse and Hospitalization in Schizophrenia ISPOR 12th Annual European Congress Paris, France, October, 2009 

Kalo Z, Pekli M, Inotai A, Remak E: PHP10 Quality assurance of fourth hurdle in Hungary – a methodological approach. ISPOR 12th Annual European Congress, Paris, France, 2009 

Nagy B, Brennan A, Skultety L, Nagy J, Szentesi A, Dessewffy Z, Kalotai Z: The cost effectiveness of rivastigmine transdermal patch in the management of patients with mild and moderate Alzheimer’s disease. III. Hungarian Health Economic Training and Conference, 2009. July 8th

Nagy J, Nagy B, Lovas K, Tolna J, Skultety L: Disease Burden in Depression. IME-META III. Hungarian Health Economic Training and Conference, 2009. July 8th 

Dr. Timar Gy, Nagyjanosi L, Dr. Kalo Z: Aclasta IME-META III.Hungarian Health Economic Training and Conference, 2009, Budapest, Hungary

Kalo Z: Strategic pricing of pharmaceuticals in the European Union. Oral presentation at the 4th International Symposium on Evidence-Based Health Care, HTA & Pricing, Central and Eastern European Society of Technology Assessment in Health Care (CEESTAHC), Krakow, Poland, 2012

 

2008

Kalo Z, Lukovics M, Verebes ED, Sampar P: PHP32 Cost-Benefit Analysis of Public Hospital Development ISPOR 11th Annual European Congress Athens, Greece, November, 2008

Bacskai M, Komaromi T, Nagy B, Kalo Z: PHP17 How mandatory price reduction of reimbursed pharmaceuticals could result in increased pharmaceutical expenditure? ISPOR 13th Annual International Meeting Toronto, Ontario, Canada, May, 2008

Inotai A, Meszaros A: PMS41 Cost-effectiveness of celecoxib compared to conventional NSAIDs and NSAID+PPI combination therapy in the treatment of rheumatoid arthritis. ISPOR 11th Annual European Congress, Athens, Greece, 2008. 

Nagy B: What sort of capitation do people need? The efficient and equitable allocation of resources. Nepszabadsag Conference 11th March 2008. 

Nagy B, Brennan A, Brandtmuller A, Thomas SK, Sullivan SD, Akehurst R: The cost-utility of the rivastigmine transdermal patch in the management of patients with moderate Alzheimer’s disease in the US. American Association for Geriatric Psychiatry Annual Meeting, Orlando, Florida, USA, 2008. March 14–17 

Nagy B, Brennan A, Brandtmüller A, Thomas SK, Gallagher M, Sullivan SD, Akehurst R: Introducing a methodology to use ADL outcomes in the assessment of the cost-effectiveness of AD treatments: a case study using rivastigmine patch. International Conference on Alzheimer's Disease, Chicago, IL, USA, 2008. July 26–31 

Nagy B, Sipos J, Dozsa Cs, Borcsek B: Implementing risk adjusted capitation payments with health care reforms: the case of Hungary. 7th European Conference on Health Economics, Roma 2008. July 24th 

Nagy B, Rakonczai P: Predicting health care expenditures with demographic characteristics for designing capitation payments in Hungary. II. Hungarian Health Economic Training and Conference, Budapest, 2008. June 9th

Kalo Z: Concepts of Pharmacoeconomics. Oral presentation at the Oncology Practice Summit Meeting, Beirut, Lebanon, 2008

Kalo Z: Value based decision-making for drug formulary inclusions. Oral presentation at the Oncology Practice Summit Meeting, Beirut, Lebanon, 2008

TODAY'S RESEARCH FOR TOMORROW'S HEALTH

Syreon Research Institute: 1142 Budapest, Mexikoi str. 65/A.

E-mail: info@syreon.eu